Human TRAIL, Mouse IgG2a Fc Tag (TRL-H5259) is expressed from human 293 cells (HEK293). It contains AA Val 114 - Gly 281 (Accession # P50591-1).
Predicted N-terminus: Glu
This protein carries a mouse IgG2a Fc tag at the N-terminus.
The protein has a calculated MW of 46.4 kDa. The protein migrates as 47-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 0.1 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human TRAIL, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human Osteoprotegerin, His Tag (Cat. No. TNB-H5220) at 5 μg/mL (100 μL/well) can bind Human TRAIL, Mouse IgG2a Fc Tag (Cat. No. TRL-H5259) with a linear range of 0.8-13 ng/mL (QC tested).
TRAIL, also known as TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.